Aclaris Therapeutics, Inc. (ACRS)

Compare

2.4550

-0.0150

(-0.61%)

As of 3:11:07 PM EST. Market Open.

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WAYNE, Pa., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) (the “Company” or “Aclaris”), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that effective January 2, 2025, the Compensation Committee of Aclaris’ Board of Directors (the Committee) granted nonstatutory stock options to purchase an aggregate of 215,000 shares of its common stock and 61,000 restricted stock units to 1 ne

GlobeNewswire 6 days ago

ACRS
-0.61%
Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

WAYNE, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 1:00 PM ET in New York, New York. A webcast of the fireside chat may be accessed through the “Events” p

GlobeNewswire last month

ACRS
-0.61%
Aclaris Therapeutics And 2 Other US Penny Stocks To Watch

As the United States market continues its upward trend, with the S&P 500 extending its winning streak and Bitcoin reaching record highs, investors are looking for opportunities beyond the well-known giants. Penny stocks, often representing smaller or newer companies, remain a relevant investment area despite their somewhat outdated name. These stocks can offer surprising value and stability when backed by solid financial foundations.

Simply Wall St. last month

SMRT

ACRS
-0.61%
ALLT
Aclaris Therapeutics upgraded to Buy from Hold at Jefferies

Jefferies upgraded Aclaris Therapeutics (ACRS) to Buy from Hold with a price target of $7, up from $2. BSI-045B is the first anti-TSLP showing clinical proof of concept in atopic dermatitis, which is likely supported by a differentiated binding profile, the analyst tells investors in a research note. The firm says the data support further development in placebo-controlled study for additional validation in AD and beyond. If successful, BSI-045B could be the first anti-TSLP in the crowded AD spac

TipRanks last month

ACRS
-0.61%
Aclaris Therapeutics upgraded to Buy from Neutral at BTIG

BTIG upgraded Aclaris Therapeutics (ACRS) to Buy from Neutral with an $8 price target In a “transformative transaction,” Aclaris has acquired full ex-China rights to an anti-TSLP humanized mAb and anti-TSLP/IL4R bispecific mAb from Chinabased Biosion, the analyst tells investors in a research note. The firm says BSI-045B’s potency is likely best-in-class with 71-times greater potency versus tezepelumab and up to nine-times higher potency versus other anti-TSLP therapies in development. Based on

TipRanks last month

ACRS
-0.61%
Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments

On Monday, Aclaris Therapeutics, Inc. (NASDAQ:ACRS) entered into an exclusive license agreement with Biosion Inc for worldwide rights (excluding Greater China) to BSI-045B and BSI-502, a preclinical-stage, novel bispecific antibody directed against both TSLP and IL4R. In a completed Phase 2a, single-arm, proof-of-concept trial in the United States in 22 patients with moderate to severe atopic dermatitis, BSI-045B was observed to have a pharmacodynamic, safety, and efficacy profile. BSI-045B is a

Benzinga last month

ACRS
-0.61%
Aclaris Therapeutics secures global rights to Biosion’s antibodies

Aclaris also announced the appointment of two key executives.

Pharmaceutical Technology last month

ACRS
-0.61%
ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs

Aclaris stock surges on inking an exclusive license agreement with Biosion for global rights to two of the latter's pipeline candidates, BSI-045B and BSI-502.

Zacks last month

ACRS
-0.61%
PFE
Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

Biosion, Inc. (Biosion), a global R&D stage biotechnology company, today announced that it has entered into an exclusive license agreement with Aclaris Therapeutics (NASDAQ: ACRS) for worldwide rights (excluding Greater China) to BSI-045B, a potential First-in-class, clinical-stage, novel anti-TSLP monoclonal antibody, and BSI-502, a potential best-in-class, pre-clinical stage, novel bispecific antibody that is directed against both TSLP and IL4R.

PR Newswire last month

ACRS
-0.61%
Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

- Enhances Aclaris’ pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned biotech executives -- Management to host conference call today at 8:30 AM ET - WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has entered into an exclusive license agreement with Biosion, Inc.

GlobeNewswire last month

ACRS
-0.61%
Aclaris Therapeutics Announces $80 Million Private Placement

WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) (the “Company” or “Aclaris”), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of 35,555,555 shares of common stock at a purchase price of $2.25 per share, for gross proceeds of approximately $80.0 millio

GlobeNewswire last month

ACRS
-0.61%
News Flash: Analysts Just Made A Meaningful Upgrade To Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Forecasts

Aclaris Therapeutics, Inc. ( NASDAQ:ACRS ) shareholders will have a reason to smile today, with the analysts making...

Simply Wall St. 2 months ago

ACRS
-0.61%
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

The analysts might have been a bit too bullish on Aclaris Therapeutics, Inc. ( NASDAQ:ACRS ), given that the company...

Simply Wall St. 2 months ago

ACRS
-0.61%
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Misses Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of -37.50% and 47.68%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

ACRS
-0.61%
Aclaris: Q3 Earnings Snapshot

WAYNE, Pa. AP) — Aclaris Therapeutics Inc. ACRS) on Wednesday reported a loss of $7.6 million in its third quarter.

Associated Press Finance 2 months ago

ACRS
-0.61%
Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

– First Patient Dosed in ATI-2138 Phase 2a Trial in Atopic Dermatitis As Previously Announced;Top-line Data Anticipated in First Half of 2025 – WAYNE, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the third quarter of 2024 and provided a corporate update. "The third quarter of 2024 marked an importan

GlobeNewswire 2 months ago

ACRS
-0.61%
Discovering Penny Stocks On US Exchanges: 3 Picks Under $100M Market Cap

As major U.S. indexes recently experienced a downturn, with technology stocks leading the decline and Treasury yields reaching a three-month high, investors are increasingly seeking opportunities beyond the usual large-cap stocks. Penny stocks, while an older term, continue to represent smaller or newer companies that may offer both affordability and growth potential for those willing to explore them. In this article, we examine three penny stocks that stand out for their financial strength...

Simply Wall St. 2 months ago

GDTC

ACRS
-0.61%
Millennium Management LLC Reduces Stake in Aclaris Therapeutics Inc

On September 30, 2024, Millennium Management LLC, a prominent hedge fund, executed a significant transaction involving the shares of Aclaris Therapeutics Inc (NASDAQ:ACRS). The firm reduced its holdings by 331,252 shares, resulting in a new total of 3,005,598 shares in the biopharmaceutical company. This move reflects a strategic adjustment in Millenniums investment portfolio, with the shares priced at $1.15 during the transaction.

GuruFocus.com 3 months ago

ACRS
-0.61%
Is BellRing Brands (BRBR) Stock Outpacing Its Medical Peers This Year?

Here is how BellRing Brands (BRBR) and Aclaris Therapeutics (ACRS) have performed compared to their sector so far this year.

Zacks 3 months ago

BRBR

ACRS
-0.61%
Aclaris doses first subject in Phase IIa atopic dermatitis treatment trial

Topline data from this trial is anticipated in the first half of next year.

Clinical Trials Arena 3 months ago

ACRS
-0.61%

Performance Overview

Return	ACRS	S&P 500
YTD	-1.01%	-1.40%
1-Year	+165.69%	+21.75%
3-Year	-77.90%	+23.23%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Aclaris Therapeutics, Inc. (ACRS)

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Aclaris Therapeutics And 2 Other US Penny Stocks To Watch

Aclaris Therapeutics upgraded to Buy from Hold at Jefferies

Aclaris Therapeutics upgraded to Buy from Neutral at BTIG

Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments

Aclaris Therapeutics secures global rights to Biosion’s antibodies

ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

Aclaris Therapeutics Announces $80 Million Private Placement

News Flash: Analysts Just Made A Meaningful Upgrade To Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Forecasts

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Aclaris Therapeutics (ACRS) Reports Q3 Loss, Misses Revenue Estimates

Aclaris: Q3 Earnings Snapshot

Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Discovering Penny Stocks On US Exchanges: 3 Picks Under $100M Market Cap

Millennium Management LLC Reduces Stake in Aclaris Therapeutics Inc

Is BellRing Brands (BRBR) Stock Outpacing Its Medical Peers This Year?

Aclaris doses first subject in Phase IIa atopic dermatitis treatment trial

Performance Overview